vs
ACM Research, Inc.（ACMR）とOrthofix Medical Inc.（OFIX）の財務データ比較。上の社名をクリックして会社を切り替えられます
ACM Research, Inc.の直近四半期売上が大きい（$244.4M vs $219.9M、Orthofix Medical Inc.の約1.1倍）。ACM Research, Inc.の純利益率が高く（3.3% vs -1.0%、差は4.3%）。ACM Research, Inc.の前年同期比売上増加率が高い（9.4% vs 2.0%）。ACM Research, Inc.の直近四半期フリーキャッシュフローが多い（$20.1M vs $16.8M）。過去8四半期でACM Research, Inc.の売上複合成長率が高い（26.7% vs 8.0%）
ACM Research, Inc.は世界の半導体製造業界向け先端プロセス装置の大手サプライヤーです。ウェハー洗浄、電気めっき、エッチングなどの高性能湿式処理システムの開発・製造・販売を手がけ、アジア、北米、欧州の半導体メーカーに製品を供給し、先端チップの生産を支援しています。
オーソフィックスメディカル社は世界的な整形外科医療機器メーカーで、脊椎インプラント、整形外科用外傷治療製品、骨成長刺激療法機器、再生医療製品の開発・製造・販売を事業としています。北米、欧州、アジア太平洋を中心に整形外科医や医療機関向けに製品を提供し、筋骨格系疾患患者の治療成績向上に取り組んでいます。
ACMR vs OFIX — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $244.4M | $219.9M |
| 純利益 | $8.0M | $-2.2M |
| 粗利率 | 40.9% | 71.1% |
| 営業利益率 | 9.4% | 0.2% |
| 純利益率 | 3.3% | -1.0% |
| 売上前年比 | 9.4% | 2.0% |
| 純利益前年比 | -74.1% | 92.4% |
| EPS（希薄化後） | $0.11 | $-0.05 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $244.4M | $219.9M | ||
| Q3 25 | $269.2M | $205.6M | ||
| Q2 25 | $215.4M | $203.1M | ||
| Q1 25 | $172.3M | $193.6M | ||
| Q4 24 | $223.5M | $215.7M | ||
| Q3 24 | $204.0M | $196.6M | ||
| Q2 24 | $202.5M | $198.6M | ||
| Q1 24 | $152.2M | $188.6M |
| Q4 25 | $8.0M | $-2.2M | ||
| Q3 25 | $35.9M | $-22.8M | ||
| Q2 25 | $29.8M | $-14.1M | ||
| Q1 25 | $20.4M | $-53.1M | ||
| Q4 24 | $31.1M | $-29.1M | ||
| Q3 24 | $30.9M | $-27.4M | ||
| Q2 24 | $24.2M | $-33.4M | ||
| Q1 24 | $17.4M | $-36.0M |
| Q4 25 | 40.9% | 71.1% | ||
| Q3 25 | 42.0% | 72.2% | ||
| Q2 25 | 48.5% | 68.7% | ||
| Q1 25 | 47.9% | 62.8% | ||
| Q4 24 | 49.6% | 69.0% | ||
| Q3 24 | 51.4% | 68.7% | ||
| Q2 24 | 47.8% | 67.8% | ||
| Q1 24 | 52.0% | 67.5% |
| Q4 25 | 9.4% | 0.2% | ||
| Q3 25 | 10.7% | -8.3% | ||
| Q2 25 | 14.7% | -7.9% | ||
| Q1 25 | 15.0% | -25.2% | ||
| Q4 24 | 19.7% | -5.3% | ||
| Q3 24 | 21.7% | -9.6% | ||
| Q2 24 | 18.6% | -12.5% | ||
| Q1 24 | 16.6% | -15.6% |
| Q4 25 | 3.3% | -1.0% | ||
| Q3 25 | 13.3% | -11.1% | ||
| Q2 25 | 13.8% | -6.9% | ||
| Q1 25 | 11.8% | -27.4% | ||
| Q4 24 | 13.9% | -13.5% | ||
| Q3 24 | 15.2% | -13.9% | ||
| Q2 24 | 12.0% | -16.8% | ||
| Q1 24 | 11.5% | -19.1% |
| Q4 25 | $0.11 | $-0.05 | ||
| Q3 25 | $0.52 | $-0.57 | ||
| Q2 25 | $0.44 | $-0.36 | ||
| Q1 25 | $0.30 | $-1.35 | ||
| Q4 24 | $0.47 | $-0.76 | ||
| Q3 24 | $0.45 | $-0.71 | ||
| Q2 24 | $0.35 | $-0.88 | ||
| Q1 24 | $0.26 | $-0.95 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $792.9M | $82.0M |
| 総負債低いほど良い | $214.0M | — |
| 株主資本純資産 | $1.5B | $450.0M |
| 総資産 | $2.9B | $850.6M |
| 負債/資本比率低いほどレバレッジが低い | 0.15× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $792.9M | $82.0M | ||
| Q3 25 | $1.1B | $62.9M | ||
| Q2 25 | $463.2M | $65.6M | ||
| Q1 25 | $475.6M | $58.0M | ||
| Q4 24 | $426.8M | $83.2M | ||
| Q3 24 | $353.8M | $30.1M | ||
| Q2 24 | $343.6M | $26.4M | ||
| Q1 24 | $230.0M | $27.0M |
| Q4 25 | $214.0M | — | ||
| Q3 25 | $242.0M | $157.2M | ||
| Q2 25 | $225.1M | $157.0M | ||
| Q1 25 | $202.5M | $156.9M | ||
| Q4 24 | $150.0M | $157.0M | ||
| Q3 24 | $150.0M | $118.5M | ||
| Q2 24 | $90.5M | $118.0M | ||
| Q1 24 | $60.0M | $118.2M |
| Q4 25 | $1.5B | $450.0M | ||
| Q3 25 | $1.4B | $442.5M | ||
| Q2 25 | $986.5M | $458.3M | ||
| Q1 25 | $949.1M | $458.3M | ||
| Q4 24 | $904.6M | $503.1M | ||
| Q3 24 | $888.2M | $525.9M | ||
| Q2 24 | $833.2M | $546.0M | ||
| Q1 24 | $796.2M | $570.3M |
| Q4 25 | $2.9B | $850.6M | ||
| Q3 25 | $2.8B | $832.6M | ||
| Q2 25 | $2.0B | $837.2M | ||
| Q1 25 | $1.9B | $823.1M | ||
| Q4 24 | $1.9B | $893.3M | ||
| Q3 24 | $1.8B | $867.9M | ||
| Q2 24 | $1.7B | $882.0M | ||
| Q1 24 | $1.6B | $906.0M |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | 0.36× | ||
| Q2 25 | 0.23× | 0.34× | ||
| Q1 25 | 0.21× | 0.34× | ||
| Q4 24 | 0.17× | 0.31× | ||
| Q3 24 | 0.17× | 0.23× | ||
| Q2 24 | 0.11× | 0.22× | ||
| Q1 24 | 0.08× | 0.21× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $33.9M | $27.7M |
| フリーキャッシュフロー営業CF - 設備投資 | $20.1M | $16.8M |
| FCFマージンFCF / 売上 | 8.2% | 7.6% |
| 設備投資強度設備投資 / 売上 | 5.6% | 4.9% |
| キャッシュ転換率営業CF / 純利益 | 4.21× | — |
| 直近12ヶ月FCF直近4四半期 | $-66.6M | $-1.3M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $33.9M | $27.7M | ||
| Q3 25 | $-4.6M | $12.4M | ||
| Q2 25 | $-44.9M | $11.6M | ||
| Q1 25 | $5.3M | $-18.4M | ||
| Q4 24 | $88.6M | $23.7M | ||
| Q3 24 | $11.9M | $11.7M | ||
| Q2 24 | $61.6M | $9.0M | ||
| Q1 24 | $-9.6M | $-18.6M |
| Q4 25 | $20.1M | $16.8M | ||
| Q3 25 | $-15.6M | $2.5M | ||
| Q2 25 | $-59.6M | $4.5M | ||
| Q1 25 | $-11.4M | $-25.1M | ||
| Q4 24 | $77.2M | $15.2M | ||
| Q3 24 | $-20.6M | $6.3M | ||
| Q2 24 | $48.5M | $-360.0K | ||
| Q1 24 | $-35.1M | $-29.1M |
| Q4 25 | 8.2% | 7.6% | ||
| Q3 25 | -5.8% | 1.2% | ||
| Q2 25 | -27.7% | 2.2% | ||
| Q1 25 | -6.6% | -13.0% | ||
| Q4 24 | 34.5% | 7.0% | ||
| Q3 24 | -10.1% | 3.2% | ||
| Q2 24 | 24.0% | -0.2% | ||
| Q1 24 | -23.0% | -15.4% |
| Q4 25 | 5.6% | 4.9% | ||
| Q3 25 | 4.1% | 4.8% | ||
| Q2 25 | 6.8% | 3.5% | ||
| Q1 25 | 9.7% | 3.5% | ||
| Q4 24 | 5.1% | 4.0% | ||
| Q3 24 | 16.0% | 2.7% | ||
| Q2 24 | 6.5% | 4.7% | ||
| Q1 24 | 16.7% | 5.6% |
| Q4 25 | 4.21× | — | ||
| Q3 25 | -0.13× | — | ||
| Q2 25 | -1.51× | — | ||
| Q1 25 | 0.26× | — | ||
| Q4 24 | 2.85× | — | ||
| Q3 24 | 0.39× | — | ||
| Q2 24 | 2.54× | — | ||
| Q1 24 | -0.55× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ACMR
| Total Single Wafer And Semi Critical Cleaning Equipment | $159.9M | 65% |
| ECP Front End And Packaging Furnace And Other Technologies | $64.1M | 26% |
| Advanced Packaging Exclude ECP Services Spares | $20.5M | 8% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
